<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.02">
 <iati-activity hierarchy="1" iati-activities:version="2.02" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities">
  <iati-identifier>XM-DAC-903-SII-38104</iati-identifier>
  <reporting-org ref="XM-DAC-903" type="40">
   <narrative xml:lang="EN">International Finance Corporation</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">Essex Bio Project</narrative>
  </title>
  <description type="2">
   <narrative xml:lang="EN">1. Increase access to quality and affordable medicine. Through the expansion of the Company&apos;&apos;s production and sale, the Project will increase the supply of quality and affordable medicines in China. In addition, Essex will keep bringing innovative medicines to the China market either through partnership with international pharmaceutical producers, such as Pfizer, or through strategic investment into some growing medical companies.   2. Demonstration Effect: Given that Essex is one of the leading biopharmaceutical companies in China with national sales coverage, a successful scaling up of their business supported by IFC&apos;&apos;s investment should have a demonstration effect in the sector.   3. Employment creation and social linkages. The Project is expected to create a number of employment opportunities for the local communities as well as spur the growth of local suppliers of goods and services.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">The proposed project involves IFC providing a convertible loan to Essex Bio-Technology Limited (Essex or the Company), which is a market leader in the development, production, and sale of biopharmaceutical drugs in China. These drugs are used in the treatment of surface wounds and a variety of eye diseases and are based on basic fibroblast growth factor (bFGF) technology. Essex is a research and development (R&amp;D) driven pharmaceutical company and holds seven innovative patents. The majority of its drugs are Category I drugs in China, meaning that they are (i) new and innovative; (ii) have not been approved or launched in any other country yet; and (iii) with a period of patent protection until 2030 and market exclusivity. The Company plans to continue investing in R&amp;D, increase its sales-force, and improve its working capital management (the Project) with a total project cost of about US$45 million equivalent.</narrative>
  </description>
  <participating-org role="4" type="70">
   <narrative xml:lang="EN">ESSEX BIO-TECHNOLOGY LIMITED</narrative>
  </participating-org>
  <participating-org activity-id="XM-DAC-903-SII-38104" ref="XM-DAC-903" role="1" type="40"></participating-org>
  <activity-status code="2"></activity-status>
  <activity-date iso-date="2016-07-06" type="1"></activity-date>
  <activity-date iso-date="2016-08-02" type="2"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">International Finance Corporation</narrative>
   </organisation>
   <telephone>+12024733800</telephone>
   <email>ccspg@ifc.org</email>
   <website>www.ifc.org</website>
   <mailing-address>
    <narrative xml:lang="EN">2121 Pennsylvania Avenue, NW Washington DC 20433</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN">Mr. Fang Haizhou, Executive Director and Managing Director Essex Bio-Technology Limited No. 88, Keji 6th Road, Hi Tech Zone, Zhuhai, Guangdong, China Tel: +86 13809801958; E-mail:  mailto:fanghaizhou@essex.com.cn  Web site:  http://www.essex.com</narrative>
   </mailing-address>
  </contact-info>
  <contact-info type="2">
   <mailing-address>
    <narrative xml:lang="EN"></narrative>
   </mailing-address>
  </contact-info>
  <recipient-country code="CN" percentage="100">
   <narrative xml:lang="EN">China</narrative>
  </recipient-country>
  <location ref="CN-China">
   <location-reach code="1"></location-reach>
   <location-id code="1453782" vocabulary="G1"></location-id>
   <name>
    <narrative xml:lang="EN">Zhuhai, Guangdong Province, China</narrative>
   </name>
   <description>
    <narrative xml:lang="EN">Location description</narrative>
   </description>
   <activity-description>
    <narrative xml:lang="EN">A description that qualifies the activity taking place at the location.</narrative>
   </activity-description>
   <administrative code="1453782" level="1" vocabulary="G1"></administrative>
   <point srsName="http://www.opengis.net/def/crs/EPSG/0/4326">
    <pos>35.0000000000 105.0000000000</pos>
   </point>
   <exactness code="2"></exactness>
   <location-class code="1"></location-class>
   <feature-designation code="ADMF"></feature-designation>
  </location>
  <sector code="621" percentage="100" vocabulary="11" vocabulary-uri="http://www.census.gov/cgi-bin/sssd/naics/naicsrch?chart=2012">
   <narrative xml:lang="EN">S-AC - Other Health Services</narrative>
  </sector>
  <country-budget-items vocabulary="1">
   <budget-item code="7.2.1" percentage="100" vocabulary="1">
    <description>
     <narrative xml:lang="EN">Total: $19.31 million</narrative>
    </description>
   </budget-item>
  </country-budget-items>
  <collaboration-type code="6"></collaboration-type>
  <default-flow-type code="35"></default-flow-type>
  <default-finance-type code="411"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget type="1">
   <period-start iso-date="2016-07-06"></period-start>
   <period-end iso-date="2017-06-30"></period-end>
   <value currency="USD" value-date="2016-07-06">19310000</value>
  </budget>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2016-07-06"></transaction-date>
   <value currency="USD" value-date="2016-07-06">19310000</value>
   <receiver-org>
    <narrative xml:lang="EN">ESSEX BIO-TECHNOLOGY LIMITED</narrative>
   </receiver-org>
   <flow-type code="35"></flow-type>
   <finance-type code="411"></finance-type>
  </transaction>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/38104/essex-bio-project">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information - Anticipated Impact Measurement &amp; Monitoring (AIMM) Assessment and Main Environmental &amp; Social Risks and Impacts of the Project</narrative>
   </title>
   <category code="A01"></category>
   <language code="EN"></language>
  </document-link>
  <document-link format="TEXT/HTML" url="https://disclosures.ifc.org/project-detail/SII/38104/essex-bio-project">
   <title>
    <narrative xml:lang="EN">Summary of Investment Information</narrative>
   </title>
   <category code="A12"></category>
   <language code="EN"></language>
  </document-link>
 </iati-activity>
</iati-activities>
